Overview

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, what effect this investigational drug has on the body, and how much should be given. This study will also measure how much of the investigational drug gets into the blood stream and how long it takes the body to get rid of it. The study has 2 parts: Part A will be conducted in healthy participants. Part B will be conducted in participants with type 1 diabetes mellitus (T1DM). This study will take approximately 10-14 days spread over 6-20 weeks, not including screening. Screening will be performed within 30 days of the start of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Boehringer Ingelheim
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc